196205-07-9

Usage

Uses

Used in Pharmaceutical Industry:
7-Bromo-1H-Indol-5-Amine is used as a building block for the synthesis of potential drug candidates and biologically active molecules. Its unique structure allows it to be a key component in the development of new therapeutic agents.
Used in Research Applications:
In the research field, 7-Bromo-1H-Indol-5-Amine is utilized as a chemical intermediate in the production of various compounds for medicinal and research purposes. Its properties make it a valuable tool for studying pharmacological and biological activities, contributing to the advancement of scientific knowledge in these areas.
Used in Chemical Synthesis:
7-Bromo-1H-Indol-5-Amine is also used in chemical synthesis processes, where its specific functional groups and structural features are exploited to create a range of different compounds with potential applications in various industries, including but not limited to pharmaceuticals, agrochemicals, and materials science.

Upstream product

• 87240-07-1 7-bromo-5-nitro-1H-indole 

Relevant academic research and scientific papers

Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists

The present invention is directed to certain novel compounds represented by structural formula I: STR1 or a pharmaceutically acceptable salt thereof, wherein R 3, R 6, R 7, R 8, R 11, R 12, R 13, A, m, n and the dashed lines are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis.

5- AND 6-(2-IMIDAZOLIN-2-YLAMINO) AND -(2-THIAZOLIN-2-YLAMINO)-BENZOTHIAZOLES AS ALPHA-2 ADRENERGIC LIGANDS

This invention is directed to indole and benzothiazole compounds which are selective for cloned human alpha 2 receptors. This invention is also related to uses of these compounds for any indication where use of an alpha 2 agonist may be appropriate. Specifically, this includes use as analgesic, sedative and anaesthetic agents. In addition, this invention includes using such compounds for lowering intraocular pressure, presbyopia, treating migraine, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal decongestion, urinary incontinence as well as for use as cognition enhancers and ocular vasoconstriction agents. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.